Market Research Logo

Dementia - Pipeline Review, H2 2016

Dementia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Dementia - Pipeline Review, H2 2016’, provides an overview of the Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dementia
  • The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects
  • The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dementia
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dementia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Dementia Overview
Therapeutics Development
Pipeline Products for Dementia - Overview
Pipeline Products for Dementia - Comparative Analysis
Dementia - Therapeutics under Development by Companies
Dementia - Therapeutics under Investigation by Universities/Institutes
Dementia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dementia - Products under Development by Companies
Dementia - Products under Investigation by Universities/Institutes
Dementia - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
AgeneBio Inc.
Alector LLC
AlzProtect SAS
Amarantus Bioscience Holdings, Inc.
Anavex Life Sciences Corp.
Axon Neuroscience SE
Axovant Sciences Ltd.
BioArctic Neuroscience AB
Biogen Inc
Biotie Therapies Corp.
Boehringer Ingelheim GmbH
Chase Pharmaceuticals Corporation
Cortice Biosciences, Inc.
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Hyundai Pharmaceutical Co., Ltd.
Ildong Pharmaceutical Co., Ltd.
Immungenetics AG
ImStar Therapeutics Inc.
Integrative Research Laboratories Sweden AB
Intellect Neurosciences, Inc.
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
M3 Biotechnology, Inc.
MediPost Co., Ltd.
Neuraltus Pharmaceuticals, Inc.
Neurimmune Holding AG
Neurodyn Inc.
Oryzon Genomics SA
Otsuka Holdings Co., Ltd.
P2D Bioscience
Pacific Northwest Biotechnology, LLC
Pivot Pharmaceuticals Inc
Sinil Pharmaceutical Co., Ltd
Stelic Institute & Co., Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sylentis S.A.U.
Takeda Pharmaceutical Company Limited
TauRx Therapeutics Ltd.
Voyager Therapeutics, Inc.
WhanIn Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Dementia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile
(donepezil hydrochloride + solifenacin succinate) - Drug Profile
AADvac-1 - Drug Profile
AD-35 - Drug Profile
ANAVEX-371 - Drug Profile
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile
ASN-561 - Drug Profile
AVP-786 - Drug Profile
AZP-2006 - Drug Profile
BAN-0805 - Drug Profile
BI-409306 - Drug Profile
CB-2233 - Drug Profile
CB-8411 - Drug Profile
choline alfoscerate SR - Drug Profile
D-217 - Drug Profile
dehydroevodiamine hydrochloride - Drug Profile
Drugs for Dementia - Drug Profile
Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile
DWJ-1365 - Drug Profile
E-2609 - Drug Profile
eltoprazine - Drug Profile
encenicline hydrochloride - Drug Profile
FRM-0334 - Drug Profile
GIBH-130 - Drug Profile
Gln-1062 - Drug Profile
GTC-6000 - Drug Profile
gugulipid - Drug Profile
HOB-075 - Drug Profile
HTL-18318 - Drug Profile
intepirdine - Drug Profile
INV-331 - Drug Profile
IRL-752 - Drug Profile
ITI-007 - Drug Profile
levetiracetam - Drug Profile
LUAF-20513 - Drug Profile
MM-201 - Drug Profile
Monoclonal Antibodies for Alzheimer’s Disease and Vascular Dementia - Drug Profile
Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile
monosodium luminol - Drug Profile
NAT - Drug Profile
nelotanserin - Drug Profile
Neurostem - Drug Profile
NI-205 - Drug Profile
NI-308 - Drug Profile
NNC-269100 - Drug Profile
NP-001 - Drug Profile
ORY-2001 - Drug Profile
P-003 - Drug Profile
PD-2015 - Drug Profile
PD-2016 - Drug Profile
PD-2024 - Drug Profile
PD-2244 - Drug Profile
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile
PST-900 - Drug Profile
salicylamine - Drug Profile
SIN-1502 - Drug Profile
Small Molecule for Dementia - Drug Profile
Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile
Small Molecules for Frontotemporal Dementia - Drug Profile
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile
Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile
Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile
SND-14 - Drug Profile
SYN-120 - Drug Profile
Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile
TAK-070 - Drug Profile
TAK-071 - Drug Profile
TauC-3 - Drug Profile
tolfenamic acid - Drug Profile
TPI-287 - Drug Profile
TRx-0237 - Drug Profile
TTT-3002 - Drug Profile
VYTAU-01 - Drug Profile
WIB-1001C - Drug Profile
zonisamide - Drug Profile
Dementia - Dormant Projects
Dementia - Discontinued Products
Dementia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dementia, H2 2016
Number of Products under Development for Dementia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
Dementia - Pipeline by AgeneBio Inc., H2 2016
Dementia - Pipeline by Alector LLC, H2 2016
Dementia - Pipeline by AlzProtect SAS, H2 2016
Dementia - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Dementia - Pipeline by Anavex Life Sciences Corp., H2 2016
Dementia - Pipeline by Axon Neuroscience SE, H2 2016
Dementia - Pipeline by Axovant Sciences Ltd., H2 2016
Dementia - Pipeline by BioArctic Neuroscience AB, H2 2016
Dementia - Pipeline by Biogen Inc, H2 2016
Dementia - Pipeline by Biotie Therapies Corp., H2 2016
Dementia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2016
Dementia - Pipeline by Cortice Biosciences, Inc., H2 2016
Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Dementia - Pipeline by Eisai Co., Ltd., H2 2016
Dementia - Pipeline by Eli Lilly and Company, H2 2016
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
Dementia - Pipeline by H. Lundbeck A/S, H2 2016
Dementia - Pipeline by Heptares Therapeutics Limited, H2 2016
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016
Dementia - Pipeline by Immungenetics AG, H2 2016
Dementia - Pipeline by ImStar Therapeutics Inc., H2 2016
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2016
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Dementia - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Dementia - Pipeline by M3 Biotechnology, Inc., H2 2016
Dementia - Pipeline by MediPost Co., Ltd., H2 2016
Dementia - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2016
Dementia - Pipeline by Neurimmune Holding AG, H2 2016
Dementia - Pipeline by Neurodyn Inc., H2 2016
Dementia - Pipeline by Oryzon Genomics SA, H2 2016
Dementia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Dementia - Pipeline by P2D Bioscience, H2 2016
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016
Dementia - Pipeline by Pivot Pharmaceuticals Inc, H2 2016
Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016
Dementia - Pipeline by Stelic Institute & Co., Inc., H2 2016
Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Dementia - Pipeline by Sylentis S.A.U., H2 2016
Dementia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Dementia - Pipeline by TauRx Therapeutics Ltd., H2 2016
Dementia - Pipeline by Voyager Therapeutics, Inc., H2 2016
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016
Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Dementia - Dormant Projects, H2 2016
Dementia - Dormant Projects (Contd..1), H2 2016
Dementia - Dormant Projects (Contd..2), H2 2016
Dementia - Dormant Projects (Contd..3), H2 2016
Dementia - Dormant Projects (Contd..4), H2 2016
Dementia - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Dementia, H2 2016
Number of Products under Development for Dementia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report